目的 觀察夏荔芪膠囊聯(lián)合左氧氟沙星治療ⅢA型慢性前列腺炎的臨床療效。方法 選取2018年6月—2019年12月在濮陽市中醫(yī)醫(yī)院就診的300例ⅢA型慢性前列腺炎，隨機(jī)分為對(duì)照組和治療組，每組各150例。對(duì)照組口服鹽酸左氧氟沙星膠囊，2粒/次，2次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服夏荔芪膠囊，3粒/次，3次/d。1周為1療程，兩組均治療6個(gè)療程。觀察兩組的臨床療效，比較兩組美國國立衛(wèi)生研究院慢性前列腺炎癥狀指數(shù)（NIH-CPSI）和前列腺液量化積分的變化情況。結(jié)果 治療后，治療組的總有效率86.21%，對(duì)照組有效率65.07%，治療組明顯高于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。與治療前相比，治療后兩組疼痛評(píng)分、尿路癥狀評(píng)分和對(duì)生活質(zhì)量影響評(píng)分均顯著降低（P<0.05）；治療后，治療組疼痛評(píng)分、尿路癥狀評(píng)分和對(duì)生活質(zhì)量影響評(píng)分顯著低于對(duì)照組（P<0.05）。治療后，兩組患者前列腺液量化積分均較治療前顯著降低（P<0.05）；治療后，治療組前列腺液量化積分顯著低于對(duì)照組（P<0.05）；治療組前列腺液量化積分前后差值顯著大于對(duì)照組（P<0.05）。結(jié)論 夏荔芪膠囊聯(lián)合左氧氟沙星治療ⅢA型慢性前列腺炎可顯著提高臨床療效，并能有效改善患者臨床癥狀，安全性較高，具有很大的臨床推廣應(yīng)用價(jià)值。

Objective To observe the therapeutic effect of Xialiqi Capsules combined with levofloxacin in treatment of ⅢA chronic prostatitis. Methods 300 Cases of ⅢA chronic prostatitis treated in Chinese Medicine Hospital of Puyang from June 2018 to December 2019 were selected and randomly divided into control group and treatment group, with 150 cases in each group. The control group were po administered with Levofloxacin Hydrochloride Capsules, 2 grains/time, twice daily. Patients in the treatment group were po administered with Xialiqi Capsules on the basis of the control group, 3 grains/time, three times daily. One course of treatment had 1 week, and both groups received 6 courses of treatment. The clinical efficacy of the two groups was observed, and the changes of chronic prostatic inflammation index (NIH-CPSI) and prostatic fluid quantitative score were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 86.21%, and the effective rate of the control group was 65.07%. The effective rate of the treatment group was significantly higher than that of the control group, with statistically significant difference between the two groups (P<0.05). Compared with before treatment, pain score, urinary tract symptom score and life quality score of the two groups were significantly reduced after treatment (P<0.05). After treatment, the pain score, urinary symptom score and life quality score of the treatment group were significantly lower than those of the control group (P<0.05). After treatment, quantitative scores of prostatic fluid in both groups were significantly lower than that before treatment (P<0.05). After treatment, the quantitative score of prostatic fluid in the treatment group was significantly lower than that in the control group (P<0.05). The difference before and after quantitative integration of prostatic fluid in the treatment group was significantly greater than that in the control group (P<0.05). Conclusion Xialiqi Capsules combined with levofloxacin can significantly improve the clinical efficacy in treatment of ⅢA chronic prostatitis, and can effectively improve the clinical symptoms of patients with high safety, which has great clinical application value.

R983

河南省科技攻關(guān)計(jì)劃項(xiàng)目（172102310306）；河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題（2019ZY1042）